SELE and acute myeloid leukemia: However, when E-selectin antagonist was administered for the last 48 h prior to BM harvest, median survival duration doubled in the recipients of high E-selectin-binding AML cells from 33 to 62.5 days (p = 0.012) (Fig. 5d, grey vs. red solid lines) indicating the blockade of E-selectin interactions significantly dampened LRC potential to initiate “relapse” under these conditions.